From Hartleys research, 16 Dec. 2016....
"APC is still undervalued on peer metrics (with better logistics, lower expected capex, and simple abstraction method) and should continue to be re-rated as the project is de-risked by development studies. "
"APC’s immediate ASX brine peers (RWD, SO4, AMN) are trading at significant market capitalisation premiums, some 2.7-3.9x higher than APC, which in our opinion appears unjustified. "
"With strong flow rates now demonstrated from the maiden test pumping we look forward to the release of the Scoping Study. "
"We maintain our Speculative Buy recommendation on APC, with a 12-month price target of 29cps. APC’s current cash positioned is just over A$5m. "
Scoping study due in March quarter. Inside ownership strong, Mark Creasy on share register, other big names accumulating.
http://australianpotash.com.au/wp-content/uploads/2016/12/APC-20161216-External1.pdf
- Forums
- ASX - By Stock
- APC
- APC vs SO4
APC vs SO4, page-5
Featured News
Add APC (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.070M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
APC (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online